Webster K. Cavenee

University of California, San Diego — United States

Medicine · Health Sciences

119h-index87.5kcitations584works3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(93), Cancer-related Molecular Pathways(72), Cancer Genomics and Diagnostics(62), Cancer, Hypoxia, and Metabolism(58), PI3K/AKT/mTOR signaling in cancer(47)

Publications583 total

Retraction of Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans
Journal of Clinical Investigation·2025Open Access
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis
Journal of Clinical Investigation·2025Open Access
A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity
Proceedings of the National Academy of Sciences·2025· 7 citedOpen Access
LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology·2024· 2 citedOpen Access
OS09.7.A GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB
Neuro-Oncology·2024· 2 citedOpen Access
Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus
Journal of Cellular Physiology·2024· 6 cited
DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma
Acta Neuropathologica Communications·2024· 9 citedOpen Access
MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis
Proceedings of the National Academy of Sciences·2023· 11 citedOpen Access
CTNI-85. GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB
Neuro-Oncology·2023· 17 citedOpen Access
P11.29.B UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology·2023Open Access
Abstract CT062: GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Cancer Research·2023· 1 cited
Supplementary Figures 1-9 from MicroRNA-138 Modulates DNA Damage Response by Repressing Histone H2AX Expression
2023Open Access
Supplementary Figure 1 from De-Repression of <i>PDGFRβ</i> Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients
2023Open Access
Data from De-Repression of <i>PDGFRβ</i> Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients
2023Open Access
Related Article from Genetic Driver Events in Premalignancy: LOH Validated for Marking the Risk of Oral Cancer
2023Open Access
Data from MicroRNA-138 Modulates DNA Damage Response by Repressing Histone H2AX Expression
2023Open Access
Supplementary Table 1 from MicroRNA-138 Modulates DNA Damage Response by Repressing Histone H2AX Expression
2023Open Access
Interview with Dr. Mischel from Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
2023Open Access
Data from Genetic Driver Events in Premalignancy: LOH Validated for Marking the Risk of Oral Cancer
2023Open Access
Interview with Dr. Mischel from Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
2023Open Access
page 1 of 30Next →

Frequent Co-authors

Frank B. Furnari(12), Paul S. Mischel(7), Timothy F. Cloughesy(6), Karen C. Arden(6), David N. Louis(5), Motoo Nagane(5), Paul Kleihues(4), Ronald A. DePinho(4), Hongyi Huang(4), Alex Koufos(4), Magnus Nordenskjöld(4), Hui Huang(4), Hiroko Ohgaki(3), Otmar D. Wiestler(3), Peter C. Burger(3), Bernd W. Scheithauer(3), Robert Bachoo(3), Akitake Mukasa(3), Cameron Brennan(3), Robert A. Phillips(3)